Details of the Drug

General Information of Drug (ID: DM9UTDE)

Drug Name

Morniflumate

Synonyms

morniflumate; 65847-85-0; UNII-R133MWH7X1; 2-Morpholinoethyl 2-((3-(trifluoromethyl)phenyl)amino)nicotinate; R133MWH7X1; Morniflumatum; Morniflumato; 2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate; Morniflumate [USAN:INN]; Morniflumatum [INN-Latin]; Morniflumato [INN-Spanish]; Nifluminsaeure 2-morpholinoethylester; UP 164; Morniflumate (USAN); Niflumic acid beta-morpholinoethyl ester; AC1Q4JLB; AC1L2HFJ; DSSTox_RID_97471; DSSTox_CID_31587; DSSTox_GSID_57798; SCHEMBL50683; CHEMBL2105059; DTXSID6057798

Indication

Disease Entry	ICD 11	Status	REF
Otitis media	AA80-AB0Z	Approved	[1]

ATC Code

M01AX22: Morniflumate

M01AX: Other antiinflammatory and antirheumatic agents, non-steroids

M01A: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

M: MUSCULO-SKELETAL SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

395.4

Logarithm of the Partition Coefficient (xlogp)

3.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The clearance of drug is 45 mL/min [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 hours [2]
Metabolism: The drug is metabolized via rapid hydrolysis in the plasma [2]

Chemical Identifiers

Formula: C19H20F3N3O3
IUPAC Name: 2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate
Canonical SMILES: C1COCCN1CCOC(=O)C2=C(N=CC=C2)NC3=CC=CC(=C3)C(F)(F)F
InChI: InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24)
InChIKey: LDXSPUSKBDTEKA-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 72106
ChEBI ID: CHEMBL136018
CAS Number: 65847-85-0
UNII: R133MWH7X1
DrugBank ID: DB09285
TTD ID: D00BDC

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN ; PGH2_HUMAN	Modulator	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Chloride anion exchanger (SLC26A3)	OTBNK2U2	S26A3_HUMAN	Gene/Protein Processing	[4]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	The pharmacokinetics and availability of niflumic acid in humans
3	Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
4	Acute regulation of the SLC26A3 congenital chloride diarrhoea anion exchanger (DRA) expressed in Xenopus oocytes. J Physiol. 2003 May 15;549(Pt 1):3-19. doi: 10.1113/jphysiol.2003.039818. Epub 2003 Mar 21.